Fosamax and Osteonecrosis of the Jaw: Scientific Evidence of Causation

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health to Occupational Exposure Concerns

The legacy context of general health and science information has long provided a foundational understanding of how pharmaceutical interventions interact with human physiology. Within this broad domain, the transition to occupational exposure concerns begins with recognizing that certain medications, while therapeutically beneficial, may introduce risks that extend beyond the patient into professional environments where healthcare workers or caregivers are involved. Fosamax, a bisphosphonate used to manage bone density disorders, has been associated with osteonecrosis of the jaw, a condition that primarily affects patients undergoing treatment. However, the scientific evidence connecting Fosamax to this adverse outcome also raises questions about exposure pathways in clinical and occupational settings. Professionals who handle, administer, or come into contact with this medication—such as dental practitioners, nurses, or pharmacy staff—may face unique considerations regarding inadvertent exposure or management of affected patients. This pivot from a general health perspective to an occupational exposure concern reframes the discussion: rather than focusing solely on patient outcomes, it becomes necessary to evaluate how the risks associated with Fosamax and osteonecrosis of the jaw translate into workplace safety protocols, handling procedures, and professional liability. The transition thus shifts the lens from therapeutic contexts to the practical realities of those who work with such pharmaceuticals daily.

Bridging to Clinical Evidence: Fosamax and ONJ

Building on the occupational context, it is essential to examine the clinical and scientific evidence that establishes a causal link between Fosamax (alendronate) and osteonecrosis of the jaw (ONJ). Fosamax is a bisphosphonate approved for osteoporosis and Paget's disease, and its mechanism involves inhibiting bone resorption, which reduces fracture risk but also alters normal bone remodeling. A recognized adverse effect is ONJ, characterized by exposed, non-healing bone in the maxillofacial region, often occurring spontaneously but generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The clinical presentation includes pain, swelling, and exposed bone that fails to heal after dental procedures. Diagnosis relies on clinical examination and imaging, with exclusion of metastatic disease or other causes. The condition has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Mechanistic Pathways Linking Fosamax to ONJ

The mechanistic pathways linking Fosamax to ONJ are rooted in its pharmacological action. Bisphosphonates like alendronate suppress osteoclast activity, reducing bone turnover. In the jawbone, which undergoes high remodeling due to dental function and infection, this suppression can impair healing after minor trauma, such as tooth extraction. Multiscale characterization of jawbone in animal models treated with bisphosphonates (alendronate) has provided comprehensive information to help understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). This research indicates that bisphosphonate treatment alters tissue mineral density distribution and mechanical properties of the jawbone matrix, potentially predisposing it to necrosis. Additionally, known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Causation and Risk Considerations for Affected Patients

Regarding causation, the evidence supports a plausible link between Fosamax use and ONJ, particularly in patients with additional risk factors. The time to onset of symptoms after starting the drug can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients experience relief of symptoms after stopping the drug, but a subset may have recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), suggesting that ONJ is a rare event that may require predisposing factors. Risk considerations for affected patients include the adequacy of warnings. The prescribing information for Fosamax includes a warning about ONJ, noting that it can occur spontaneously and is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the optimal duration of Fosamax use has not been determined, and for patients at low-risk for fracture, drug discontinuation after 3 to 5 years of use is considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This suggests that long-term exposure may increase risk, but the decision to discontinue must balance fracture prevention benefits. Causation-related considerations for affected patients involve establishing a temporal relationship between Fosamax exposure and ONJ onset. The timeline can be variable, from days to months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Patients who develop ONJ after dental procedures while on Fosamax may have a stronger causal link, especially if other risk factors are present. The recurrence of symptoms upon rechallenge further supports causation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, because ONJ can occur spontaneously in the absence of bisphosphonate use, individual assessment is necessary. In summary, the scientific evidence connects Fosamax to ONJ through pharmacological mechanisms that impair jawbone healing, supported by clinical reports and animal studies. The risk is heightened by duration of use and concurrent dental procedures. Adequate warnings exist in the prescribing information, but patients and clinicians should remain vigilant, particularly when invasive dental work is planned. The timeline between exposure and harm can be short, and discontinuation may reduce risk, though benefits of osteoporosis treatment must be weighed.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the scientific evidence linking Fosamax to osteonecrosis of the jaw?

The evidence includes pharmacological mechanisms where bisphosphonates like Fosamax suppress osteoclast activity, impairing jawbone healing. Clinical reports and animal studies support this link, with risk factors including invasive dental procedures and long-term use. Sources: (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56) and (https://pubmed.ncbi.nlm.nih.gov/40345077/).

How long after starting Fosamax can osteonecrosis of the jaw occur?

The time to onset can vary from one day to several months after starting the drug, as noted in prescribing information (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What are the risk factors for developing ONJ while on Fosamax?

Risk factors include invasive dental procedures, cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids), poor oral hygiene, and co-morbid disorders like periodontal disease. Duration of bisphosphonate use also increases risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Check Whether Your Situation Qualifies

Free and confidential. No obligation — an initial records screening only.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.